Combining conjugated estrogens (CE) with the selective estrogen receptor modulator bazedoxifene (BZA) is a novel, orally administered menopausal therapy. We investigated the effect of CE/BZA on insulin sensitivity, energy metabolism, and serum metabolome in postmenopausal women with obesity.
Pubmed ID: 32698159 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets Osteocalcin
View all literature mentionsThis unknown targets
View all literature mentionsThis unknown targets
View all literature mentionsThis unknown targets C-Reactive Protein (CRP)
View all literature mentionsThis unknown targets LCN2
View all literature mentionsThis unknown targets RBP4
View all literature mentionsThis unknown targets SERPINE1
View all literature mentionsThis unknown targets
View all literature mentionsThis monoclonal targets FGF-21
View all literature mentions